MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs) - Concepedia

Concepedia

Publication | Closed Access

MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

11

Citations

0

References

2023

Year

Jean‐Jacques Kiladjian, Claire Harrison, Ruben A. Mesa, Haifa Kathrin Al‐Ali, John Mascarenhas, Fabián Sanabria, Julie Vienne Bürki, Bourras‐Rezki Bengoudifa, Francesco Passamonti

Clinical Lymphoma Myeloma & Leukemia

No additional data available for this publication yet. Check back later!